SEQENS CDMO Revenue and Competitors
Estimated Revenue & Valuation
- SEQENS CDMO's estimated annual revenue is currently $27.9M per year.
- SEQENS CDMO's estimated revenue per employee is $294,095
Employee Data
- SEQENS CDMO has 95 Employees.
- SEQENS CDMO grew their employee count by -17% last year.
SEQENS CDMO's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Customer Service Officer | Reveal Email/Phone |
2 | Head BU Supply Chain - Generics BU | Reveal Email/Phone |
3 | Head Tech Transfer and Kilo Lab | Reveal Email/Phone |
4 | Head Sales Europe & Asia - Category Manager Custom Synthesis Small Molecules & Pharmachemicals | Reveal Email/Phone |
5 | Associate Director CMC | Reveal Email/Phone |
6 | Business Support Officer | Reveal Email/Phone |
7 | QA Director, QP | Reveal Email/Phone |
8 | Supply Chain Manager | Reveal Email/Phone |
9 | Supply chain Manager | Reveal Email/Phone |
10 | QC Laboratory Manager | Reveal Email/Phone |
SEQENS CDMO Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | N/A | 2665 | -3% | $200M | N/A |
What Is SEQENS CDMO?
Emergence of a new global CDMO Three custom development and manufacturing organizations – PCAS S.A. in France, Chemie Uetikon in Germany and PCI Synthesis in the United States – have joined forces as Seqens CDMO (formerly Novacap) to offer world-class Drug Substance Development and Manufacturing services to the pharmaceutical industry. With three R&D centers, six cGMP / FDA inspected production sites in Europe and the United States supported by two manufacturing sites for the production of critical intermediates and Regulatory Starting Materials (RSMs), the group offers a powerful manufacturing network employing approximately 1200 persons capable to embrace complexity in developing, industrializing and manufacturing complex molecular entities.
keywords:N/A
N/A
Total Funding
95
Number of Employees
$27.9M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SEQENS CDMO News
Increases R&D capability and productivity in the U.S. and builds on merger with CDMO Wavelength Pharmaceuticals. 03.21.22. SEQENS, a manufacturer of active...
French CDMO Seqens has signed a multimillion-dollar deal to add an R&D laboratory in Devens, Mass., which is about an hour from its US manufacturing...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20M | 95 | 30% | N/A |
#2 | N/A | 95 | -2% | N/A |
#3 | $31.2M | 95 | -4% | N/A |
#4 | $16M | 95 | 51% | N/A |
#5 | $7.5M | 95 | 1% | N/A |